Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Three-arm randomized non-inferiority pilot study of anticoagulation during ECMO
2022-002259-20Phase 4Active
- Sponsor
- Medical University of Vienna
- Start
- Feb 2023
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial in respiratory failure and None comparing Enoxaparin arm, Argatroban arm and Heparin arm (3 arms). Primary endpoint: Incidence of thromboembolic events during ECMO therapy. Started Feb 2023; status: active.
02
Drugs
enoxaparinargatrobanheparin
03
Conditions
respiratory failure
Beyond the preview
Go deeper on 2022-002259-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002259-20.